Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute Kidney Injury (AKI) is characterized by a sudden loss of kidney function, significantly increasing the risk of mortality and progression to chronic kidney disease (CKD). Current diagnostic approaches, primarily based on serum creatinine (SCr) levels, are inadequate for early detection, as SCr can remain within normal ranges during the initial stages of injury. This study explores the potential of non-invasive optoelectronic techniques—specifically fluorescence and Raman spectroscopy—for identifying urinary biomarkers associated with AKI and CKD, aiming to enhance early diagnosis and clinical decision-making.
Urine samples were collected from anonymous volunteers participating in the LUMINA project and from patients in the Nephrology Unit, following informed consent. The study included samples from healthy individuals (n=7), CKD patients (n=6), and AKI patients (n=2). Standard creatinine solutions (1.25–100 mg/dL) were also prepared as spectral references.
Fluorescence measurements were performed using a Jasco FP-8300 spectrofluorometer and 1 cm path length quartz cuvettes. Three-dimensional (3D) fluorescence spectra were acquired by varying excitation and emission wavelengths at room temperature. Raman spectra were obtained using a 532 nm laser-equipped spectrometer at ISEL, under the LUMINA project framework. Data analysis focused on identifying distinct spectral features associated with pathological conditions.
Fluorescence spectroscopy effectively differentiated creatinine concentrations and revealed distinct spectral signatures between healthy and pathological samples. Urine from AKI and CKD patients exhibited increased fluorescence in emission regions corresponding to aromatic amino acids and protein metabolites (notably tryptophan), indicating biomarker accumulation.
Conversely, Raman spectroscopy demonstrated limited sensitivity to creatinine due to background noise and the poor scattering efficiency of polar molecules. Nevertheless, spectra from some CKD samples showed peaks potentially attributable to calcium oxalate within the 400–600 cm⁻¹ range. Increasing laser power from 5 mW to 80 mW significantly improved signal intensity, signal-to-noise ratio, and spectral clarity, revealing consistent patterns in this wavenumber range across different sample groups.
Fluorescence spectroscopy shows strong potential as a rapid, non-invasive technique for early AKI detection and differentiation between healthy and diseased individuals. While Raman spectroscopy currently faces technical limitations, its utility could be enhanced with further calibration and optimization. Together, these optoelectronic methods present a promising dual-modality approach to nephrological diagnostics, offering spectral validation that could facilitate earlier and more effective clinical intervention.
